|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
A PCR product of the expected size of 334 bp, corresponding to SSTR1, was expressed only in EC from prostate cancer, whereas the expected 461-bp product of SSTR2 was found only in EC from normal prostate.
|
9253335 |
1997 |
|
Malignant neoplasm of prostate
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
No clear association between prostate cancer risk and genetic variation of the SST and SSTR1-5 genes was identified.
|
19423539 |
2009 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Somatostatin (SST) and SST receptors (SS1R, SS2R, SS3R, SS4R and SS5R) appear to play a significant role in the progression of human prostate cancer (PCa), which is associated with heterogeneity of SSRs expression and specific cell localization as we already demonstrated in the LNCaP cell line, an in vitro model of human androgen-dependent PCa.
|
24211300 |
2014 |
|
Prostate carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
No clear association between prostate cancer risk and genetic variation of the SST and SSTR1-5 genes was identified.
|
19423539 |
2009 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
A PCR product of the expected size of 334 bp, corresponding to SSTR1, was expressed only in EC from prostate cancer, whereas the expected 461-bp product of SSTR2 was found only in EC from normal prostate.
|
9253335 |
1997 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, our data revealed that SSTR1/sst1 expression might be regulated by specific miRNAs in PCa, including miR-24, which is downregulated in PCa samples and correlates inversely with SSTR1 expression.
|
28905400 |
2017 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Somatostatin (SST) and SST receptors (SS1R, SS2R, SS3R, SS4R and SS5R) appear to play a significant role in the progression of human prostate cancer (PCa), which is associated with heterogeneity of SSRs expression and specific cell localization as we already demonstrated in the LNCaP cell line, an in vitro model of human androgen-dependent PCa.
|
24211300 |
2014 |
|
Acromegaly
|
0.020 |
Biomarker
|
disease |
BEFREE |
Treatment with available synthetic somatostatin analogues (SSAs) is considered the mainstay in the medical management of acromegaly which exert their beneficial effects through the binding to a family of G-protein coupled receptors encoded by 5 genes (SSTR1-5).
|
30650942 |
2019 |
|
Acromegaly
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.
|
29455389 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Results showed that there was no significant difference between SSTR1 and SSTR2 polymorphism frequencies in the tested breast cancer population (P = 0.59 and P = 0.54, respectively) nor the solar keratosis population (P = 0.10 and P = 0.883, respectively) as compared to unaffected populations.
|
11311492 |
2001 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study revealed that SSTR1 and SSTR4 are the most frequently expressed SSTR subtypes in breast cancer, and that the cell cycle arrest was mediated by SSTR1/SSTR4 dimerization/activation.
|
30675231 |
2019 |
|
Carcinoid Tumor
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
SSTR1-5 messenger RNA (mRNA) transcripts were investigated in 38 endocrine GEP tumours (32 islet cell tumours, six carcinoid) using reverse transcriptase polymerase chain reaction (RT-PCR), and their distribution was analysed with respect to tumour characteristics and scintigraphy imaging.
|
9279525 |
1997 |
|
Carcinoid Tumor
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
SSTR1 to SSTR5 expression in PC tumors.
|
30657933 |
2019 |
|
Endometriosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The positive rates of SSTR1-5 expression in the eutopic endometrium from 12 patients with EMS were 33.3, 41.7, 58.3, 58.3 and 83.3%, respectively, while the positive rates of SSTR1-5 expression in the normal endometrium from 14 women without EMS were 7.1, 7.1, 21.4, 28.6 and 64.3%, which were lower than the positive rates of SSTR1-5 in the EE (43.3, 70, 53.3, 50 and 96.7%) and eutopic endometrial cells (33.3, 41.7, 58.3, 58.3 and 83.3%).
|
30405748 |
2018 |
|
Endometriosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of somatostatin receptors (SSTR1, 2, and 5) in human endometrial tissue and its ectopic form has been previously studied and may be different in each type of endometriosis.
|
29750706 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
We found that SSTR1 is overexpressed in multiple cohorts of PCa samples, as compared with normal prostate tissues, wherein it correlates with androgen receptor (AR) expression, and appears to be associated with aggressiveness (metastasis).
|
28905400 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Immunoreactivity of sstr1, sstr2a and sstr4 tended to decrease as tumor aggressiveness increased. sstr5 showed an opposite pattern, with higher staining in well-differentiated carcinomas compared with well-differentiated tumors. sstr5 immunoreactivity was correlated with the presence of metastases and angioinvasion, suggesting a possible association with more aggressive behavior.
|
22156600 |
2012 |
|
Prolactinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Consequently, the mRNAs of SSTR subtypes (SSTR) 1, 2, 3, and 5, dopamine receptor (D2R), and ERα were measured by real-time quantitative RT-PCR in 59 NFomas and 50 functioning adenomas; the latter included 30 GH-secreting adenomas (GHomas) and 20 prolactinomas (PRLomas).
|
20797424 |
2011 |
|
Prolactinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, prolactinomas have a specific pattern of SSTR subtype mRNA expression (SSTR5 and SSTR1).
|
10487698 |
1999 |
|
Thyroid Neoplasm
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We investigated the mRNA expression of SSTR1-5 in benign and malignant epithelial thyroid tumours [20 cold thyroid nodules (CTNs), 20 toxic thyroid nodules (TTNs), 20 papillary, 20 follicular, and 5 anaplastic carcinomas (PTCs, FTCs, ATCs, respectively)] and compared them to normal surrounding thyroid tissues.
|
20094970 |
2010 |
|
Small cell carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The levels of expression of SSTR1 mRNA were higher in both SCLC and squamous cell carcinoma than in adenocarcinoma cell lines.
|
7968260 |
1994 |
|
Small cell carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
SSTR1 was detected in approximately 65% of the TC and AC, but hardly in the SCLC, whereas both SSTR2A and SSTR5 were present in approximately 45% of each entity.
|
25494861 |
2015 |
|
Pituitary-dependent Cushing's disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present study suggests that somatostatin analogs more selective for SSTR5 and for SSTR1 and/or 2may have the therapeutic potential for medical treatment of CD and SCA, respectively, whereas clinical application of dopamine agonists selective for D2R is very limited in either CD or SCA.
|
19318729 |
2009 |
|
Pituitary-dependent Cushing's disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
There are marked expression differences of SSTR1-5 as well as changes in expression in recurrent disease that need to be addressed when looking for other possible substances for the treatment of Cushing's disease.
|
30627156 |
2018 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
SSTR-2, SSTR-5, and SSTR-1 are thought to play major roles in inhibiting pancreatic cancer growth both in vitro and in vivo.
|
15706439 |
2005 |